Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Tgen professor to receive 2014 Hope Funds Award for developing numerous cancer treatments

Tgen professor to receive 2014 Hope Funds Award for developing numerous cancer treatments

Cytrx releases statement in response to two recent lawsuits

Cytrx releases statement in response to two recent lawsuits

Scientists discover why cerebellar granule cell neurons in A-T patients fail to repair DNA damage

Scientists discover why cerebellar granule cell neurons in A-T patients fail to repair DNA damage

XBP1 gene plays pivotal role in the growth and progression of triple negative breast cancer

XBP1 gene plays pivotal role in the growth and progression of triple negative breast cancer

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

Rare abnormality in chromosomes increases risk of rare childhood leukaemia

Rare abnormality in chromosomes increases risk of rare childhood leukaemia

Imaging cancer in children using MRI: an interview with Dr. Heike E. Daldrup-Link, Stanford University School of Medicine

Imaging cancer in children using MRI: an interview with Dr. Heike E. Daldrup-Link, Stanford University School of Medicine

New drug for patients with leukaemia and lymphoma puts an end to chemotherapy

New drug for patients with leukaemia and lymphoma puts an end to chemotherapy

States highlights: N.C. Medicaid overhaul; Conn. 'aid in dying' bill; Calif. Medical expenses crowdfunding

States highlights: N.C. Medicaid overhaul; Conn. 'aid in dying' bill; Calif. Medical expenses crowdfunding

Findings open way to identification of new cancer drugs to fight acute myeloid leukemia

Findings open way to identification of new cancer drugs to fight acute myeloid leukemia

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Researchers examine how diabetes drug can benefit cancer patients

Researchers examine how diabetes drug can benefit cancer patients

Merck Millipore announces joint development agreement with Sysmex Corporation

Merck Millipore announces joint development agreement with Sysmex Corporation

Dartmouth researchers develop unique approach to treat Chronic Lymphocytic Leukemia

Dartmouth researchers develop unique approach to treat Chronic Lymphocytic Leukemia

Researcher discover new chemical class that attacks two key cancer cell building block targets

Researcher discover new chemical class that attacks two key cancer cell building block targets

Researchers examine mothers’ condition during maintenance period after child's treatment for ALL

Researchers examine mothers’ condition during maintenance period after child's treatment for ALL

A pill may provide hope to relapsed leukemia and lymphoma patients

A pill may provide hope to relapsed leukemia and lymphoma patients

Researchers find that protein synthesis can be studied in adult stem cells

Researchers find that protein synthesis can be studied in adult stem cells

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.